BioXcel Therapeutics, Inc.BTAIEarnings & Financial Report
BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm that leverages artificial intelligence to accelerate drug discovery and development. Its core focus is on neuroscience and immuno-oncology therapies addressing unmet medical needs, primarily serving markets in North America with candidates targeting rare and hard-to-treat conditions.
BTAI Q4 FY2025 Key Financial Metrics
Revenue
$256.0K
Gross Profit
$224.0K
Operating Profit
$-10.3M
Net Profit
$-12.5M
Gross Margin
87.5%
Operating Margin
-4016.4%
Net Margin
-4900.4%
YoY Growth
-30.1%
EPS
$0.40
BioXcel Therapeutics, Inc. Q4 FY2025 Financial Summary
BioXcel Therapeutics, Inc. reported revenue of $256.0K (down 30.1% YoY) for Q4 FY2025, with a net profit of $-12.5M (down 15.5% YoY) (-4900.4% margin). Cost of goods sold was $32.0K, operating expenses totaled $10.5M.
Key Financial Metrics
| Total Revenue | $256.0K |
|---|---|
| Net Profit | $-12.5M |
| Gross Margin | 87.5% |
| Operating Margin | -4016.4% |
| Report Period | Q4 FY2025 |
BioXcel Therapeutics, Inc. Annual Revenue by Year
BioXcel Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $642.0K).
BioXcel Therapeutics, Inc. Quarterly Revenue & Net Profit History
BioXcel Therapeutics, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $256.0K | -30.1% | $-12.5M | -4900.4% |
| Q3 FY2025 | $98.0K | -54.2% | $-30.9M | -31541.8% |
| Q2 FY2025 | $120.0K | -89.1% | $-19.2M | -15989.2% |
| Q1 FY2025 | $168.0K | -71.1% | $-7.3M | -4317.9% |
| Q4 FY2024 | $366.0K | -2.7% | $-10.9M | -2966.9% |
| Q3 FY2024 | $214.0K | -37.2% | $-13.7M | -6378.5% |
| Q2 FY2024 | $1.1M | +141.6% | $-8.3M | -751.7% |
| Q1 FY2024 | $582.0K | +182.5% | $-26.8M | -4603.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $582000 | $1.1M | $214000 | $366000 | $168000 | $120000 | $98000 | $256000 |
| YoY Growth | 182.5% | 141.6% | -37.2% | -2.7% | -71.1% | -89.1% | -54.2% | -30.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $82.3M | $65.4M | $48.9M | $38.3M | $38.6M | $25.8M | $44.8M | $44.9M |
| Liabilities | $154.7M | $139.7M | $134.5M | $131.4M | $128.7M | $133.5M | $133.7M | $140.4M |
| Equity | $-72.4M | $-74.3M | $-85.6M | $-93.1M | $-90.2M | $-107.7M | $-88.9M | $-95.5M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-17.7M | $-23.2M | $-16.3M | $-14.8M | $-12.0M | $-12.6M | $-18.8M | $-14.2M |